Evaluating Stroke and Hemorrhage Risks Associated with Non–Vitamin K Oral Anticoagulants in Patients with Nonvalvular Atrial Fibrillation - Takeaways - MDSpire

Evaluating Stroke and Hemorrhage Risks Associated with Non–Vitamin K Oral Anticoagulants in Patients with Nonvalvular Atrial Fibrillation

  • By

  • Marie C. Bradley

  • Andrew L. Simon

  • Joy Kolonoski

  • David J. Graham

  • Rongmei Zhang

  • John G. Connolly

  • April 24, 2026

  • 0 min

Share

  • 1

    Non-vitamin K oral anticoagulants (NOACs) are effective for stroke prevention in patients with nonvalvular atrial fibrillation (NVAF).

  • 2

    Observational studies have compared NOACs, but few included younger users or adequately adjusted for confounding factors.

  • 3

    A large study using Medicare data found rivaroxaban had a less favorable benefit-harm profile in patients aged 65 and older with NVAF.

  • 4

    The cohort study analyzed NOAC safety and effectiveness among users younger than 65 years using data from the FDA Sentinel System.

  • 5

    Outcomes measured included major extracranial bleeding and thromboembolic stroke, using validated algorithms for accurate diagnosis.

Original Source(s)

Evaluating Stroke and Hemorrhage Risks Associated with Non–Vitamin K Oral Anticoagulants in Patients with Nonvalvular Atrial Fibrillation

  • by Marie C. Bradley, Andrew L. Simon, Joy Kolonoski, David J. Graham, Rongmei Zhang, John G. Connolly

  • April 24, 2026

Related Content

Tirofiban After Tenecteplase in Stroke

Adjunctive tirofiban was linked to higher rates of positive 90-day outcomes in acute ischemic stroke.

Occludin-mediated barrier dysfunction and its role in cardiovascular and cerebrovascular pathogenesis

Serum Urate Goals Tied to Lower CV Risk

Patients with gout who reached serum urate targets had modestly higher 5-year cardiovascular event-free survival, with associations strongest among high-risk patients